2023
CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)
Kewan T, Mirza S, Pine A, Rasheed Y, Hamouche R, Leveille E, Goshua G, Gu S, Liu Y, Vanoudenhove J, Bar N, Neparidze N, Foss F, Gowda L, Isufi I, Halene S, Lee A, Seropian S. CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS). Blood 2023, 142: 2132. DOI: 10.1182/blood-2023-187295.Peer-Reviewed Original ResearchCytokine release syndromeDiffuse large B-cell lymphomaCAR T-cell therapyCAR T-cell productsCAR-T productsNon-Hodgkin lymphomaBest cutoff pointMultiple myelomaHigher oddsDay 3Risk factorsTime pointsCutoff pointDay 5Day 0Median absolute lymphocyte countChimeric antigen receptor T cellsRefractory non-Hodgkin lymphomaCAR T-cell infusionAntigen receptor T cellsLarge B-cell lymphomaCAR-T activationFludarabine/cyclophosphamideHigher baseline CRPPossible inflammatory mediators
2010
Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older
Toomey C, Muzikanksy A, Lee A, Barnes J, Michaelson J, Abramson J, Hochberg E. Treatment Choice and Outcome In Diffuse Large B Cell Lymphoma (DLBCL) Patients 75 Years and Older. Blood 2010, 116: 733. DOI: 10.1182/blood.v116.21.733.733.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCharlson Comorbidity IndexPatients age 75Patients 75 yearsUse of anthracyclinesComorbidity indexAge 75Elderly patientsOverall survivalPerformance statusPrognostic factorsSpeakers bureauModern chemotherapyAdvanced stageMedian Charlson comorbidity indexOutcome of DLBCLDiagnosis of DLBCLDischarge summariesLarge B-cell lymphomaExtranodal disease sitesHealth-related comorbiditiesECOG performance statusMedian overall survivalPatients 80 yearsAnn Arbor stage
2009
Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL).
Hochberg E, Birrer N, Toomey C, Barnes J, Lee A, LaCasce A, Abramson J. Rituximab Does Not Improve Progression Free (PFS) or Overall Survival (OS) in Patients with Limited Stage Diffuse Large B Cell Lymphoma (DLBCL). Blood 2009, 114: 3755. DOI: 10.1182/blood.v114.22.3755.3755.Peer-Reviewed Original ResearchLimited stage diffuse large B-cell lymphomaDiffuse large B-cell lymphomaLarge B-cell lymphomaUse of rituximabOverall survivalB-cell lymphomaSpeakers bureauCell lymphomaYounger low-risk patientsPrimary diffuse large B-cell lymphomaDana-Farber Cancer InstituteBenefit of rituximabGood-prognosis populationMultiple retrospective analysesAnthracycline-containing chemotherapyOverall survival benefitPatients 18 yearsLow-risk patientsAdvanced-stage patientsCD20 monoclonal antibodyLarge multicenter trialsTumor registry dataYears of ageMassachusetts General HospitalCurative intent